Bacterial resistance to antibiotics has made it necessary to resort to using antibacterial drugs that have considerable toxicities. Here, we show that conjugation of vancomycin-loaded nanoparticles with the cyclic 9-amino-acid peptide CARGGLKSC (CARG), identified via phage display on Staphylococcus aureus (S. aureus) bacteria and through in vivo screening in mice with S. aureusinduced lung infections, increases the antibacterial activity of the nanoparticles in S. aureus-infected tissues and reduces the systemic dose needed, minimizing side effects. CARG binds specifically to S. aureus bacteria but not Pseudomonas bacteria in vitro, selectively accumulates in S. aureus-infected lungs and skin of mice but not in non-infected tissue and Pseudomonas- 
S
taphylococcus aureus is one of the most common pathogens causing invasive infections, both in healthcare settings and in communities [1] [2] [3] . S. aureus infections can be severe and life threatening, and can cause abscesses, endocarditis, pneumonia, toxic shock syndrome and sepsis. Methicillin-resistant S. aureus (MRSA), in particular, is now of great concern and represents a significant public health problem 4 . The resistance of MRSA to the commonly used and relatively non-toxic first-line antibiotics makes it necessary to treat serious infections with antibiotics such as vancomycin that are kept in reserve or avoided because of their toxicity. These antibiotics can have serious adverse effects including thrombophlebitis, fever, kidney damage, epidermal necrolysis and a hypersensitivity reaction known as red man syndrome, potentially resulting in toxic symptoms worse than the infection itself [5] [6] [7] . In the USA, about half a million people acquire a staphylococcal infection annually and the healthcare costs related to these infections exceed US$14 billion per year 8, 9 . Therefore, there is an urgent need to develop better therapies. One solution is to find new and safer antibacterial drugs. Alternatively, existing last-resort antibiotics could be selectively delivered to the infected site, in order to increase drug potency locally and reduce side effects elsewhere.
One approach to reduce the toxicity of antibiotics is to improve their pharmacokinetics, particularly by packaging the drug into nanoparticles [10] [11] [12] [13] [14] . Nanoparticle formulations can prolong the halflife of the antibiotic payload and serve as a sustained release system, reducing the frequency of administration and improving the therapeutic index. Active targeting of an antibiotic to bacteria in an infected tissue is another strategy that can be used to increase their therapeutic index. In recent years, rapid advances have been made in targeted drug delivery systems, but mostly in cancer treatment [15] [16] [17] [18] [19] . In the context of infectious disease, a rifampicin derivative has been coupled to an anti-MRSA antibody to treat systemic MRSA infections in a mouse model 20 . The conjugate was more effective than the free antibiotic. More importantly, the targeted therapeutic appeared to reach intracellular bacteria, which otherwise could have been 'hidden' from the antibiotic to become a latent source of recurrent infection.
The combination of nanoparticle delivery with specific tissue targeting provides a particularly powerful means of improving drug delivery. Here we develop a targeted nanoparticle system to improve the delivery of antibiotics. The nanoparticles in this system have a biocompatible porous silicon core that provides a high loading capacity for drugs and a readily modified surface to accommodate targeting groups [21] [22] [23] [24] [25] [26] . To develop targeting devices for the nanoparticles, we employed in vivo screening of phage-displayed peptide libraries to identify peptides that recognize sites of bacterial infection. This has been found to be a powerful and unbiased way of discovering peptides that specifically home to other diseased tissues, such as tumours, atherosclerotic plaques and tissue injuries [27] [28] [29] [30] .
Here we show that it also lends itself to infection targeting.
. The screen consisted of an in vivo round on infected lungs, a round of in vitro screening on cultured S. aureus bacteria to eliminate healthy tissue binders, and another in vivo round on infected lungs. High-throughput sequencing and consensus motif analysis of the recovered phage pool revealed a dominant shared sequence motif, ARG or ARGG, among the peptides encoded by the phages (Fig. 1) . A consensus sequence was used to generate a synthetic 9-amino acid cyclic peptide named CARG (sequence: CARGGLKSC).
The CARG peptide, synthesized with a 5(6)-carboxyfluorescein label (FAM-CARG), bound S. aureus bacteria in vitro, whereas a control peptide, with the same overall structure and charge (approximately + 2) (sequence: CNREARGRC) showed no binding (Fig. 2a) . Further analysis of the binding by super-resolution microscopy showed that the peptide binds to the surface of the bacteria (Fig. 2b) . We also tested the ability of the CARG peptide to recognize a clinical isolate of MRSA. The FAM-CARG strongly bound to the MRSA strain USA300-0114 ( Supplementary Fig. 1 ), a community-associated strain responsible for outbreaks of staphylococcal skin and soft-tissue infections in the USA 32 . Moreover, the FAM-CARG peptide also bound to Streptococcus pyogenes in culture ( Supplementary  Fig. 2 ), suggesting that it also to other gram-positive strains.
In agreement with the in vitro binding results, intravenously injected CARG peptide homed to S. aureus-infected lungs, accumulating at the site of infection (Fig. 2c,d ). There was only negligible homing to the healthy lungs of mice with a sham infection.
Quantification of the FAM fluorescence signal showed that CARG accumulated in the infected regions of the lungs at levels 10-fold higher than in healthy lungs (Fig. 2e) . Intravenously injected FAM-CARG peptide strongly homed to and accumulated at the infected tissue in a S. aureus skin infection model, and there was no detectable accumulation in uninfected skin (Fig. 3a,b) . The control peptide for CARG showed essentially no homing to the S. aureusinfected lungs ( Supplementary Fig. 3a) .
We also tested a linearized version of the CARG peptide, where the terminal cysteines are replaced with alanines (sequence: AARGGLKSA). This linear ARG peptide showed negligible homing to the infected lungs ( Supplementary Fig. 3b ). Finally, we showed that CARG does not recognize cultured Pseudomonas aeruginosa bacteria or lung tissue infected with these bacteria ( Supplementary  Fig. 3c ). We also tested a Pseudomonas-binding peptide (sequence: EKRTKSRLM) 33 on S. aureus-infected lungs. This peptide, which shows strong binding to P. aeruginosa cultures in vitro and homes to Pseudomonas lung infection in vivo ( Supplementary Fig. 4a ), did not show any homing to S.aureus-infected lungs ( Supplementary  Fig. 4b ). These results show that CARG recognizes S. aureus infections in different tissues, and suggest that it is highly specific for S. aureus with some level of specificity to at least streptococci among the category of gram-positive bacteria.
CARG partially colocalizes with S. aureus and inflammatory leukocytes at sites of infection. S. aureus is generally an extracellular pathogen, but it is also capable of invading and surviving inside mammalian phagocytic cells responsible for bacterial clearance [34] [35] [36] [37] . The intracellular localization provides the bacteria protection against the host immune system and antibiotics, leading to aureus-induced pneumonia model. Lung infection was generated by direct inoculation of S. aureus into the lungs by intratracheal surgery. 48-72 h after the bacterial inoculation, a CX 7 C-peptide library was screened by in vivo phage display. After three in vivo rounds, the enriched phage pool was subjected to in vitro biopanning on cultured S. aureus. The in vitro phage pool was further screened in vivo in infected animals. The graph shows the enrichment obtained in four rounds of in vivo biopanning. The recovered phage pools were subjected to high-throughput sequencing and the data were analysed for dominant binding motifs.
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recurrent infections 38, 39 . To determine whether the CARG peptide targets the bacteria and enters into host cells harbouring intracellular bacteria, we intravenously injected S. aureus-infected mice with FAM-CARG and found that the injected peptide partially colocalized with the bacteria (Fig. 4a ) and cells harbouring intracellular bacteria (Fig. S5 ) in infected lung tissue. Quantitative colocalization analysis of the confocal immunofluorescence images showed 21.5 ± 2.2% colocalization of the FAM-CARG signal with the bacterial immune staining in infected lungs. Polymorphonuclear leukocytes (neutrophils) are a primary cellular host defense mechanism against S. aureus infections, and S. aureus abscesses are mostly composed of these cells 40 . S. aureus-infected lungs were rich in inflammatory leukocytes (Fig. 4b) , and the cells with engulfed bacteria were primarily neutrophils (Fig. 4c) , as they expressed the neutrophil-specific marker Ly-6G 41 . Analysis of CARG homing to S. aureus-infected skin sections also showed a colocalization of CARG with leukocytes at sites of infection ( Supplementary Fig. 6 ).
Thus, CARG-mediated targeting of antibiotics to neutrophils that contain intracellular S. aureus could potentially be harnessed to eradicate persistent infections 41 .
CARG-conjugated nanoparticles as a carrier of therapeutics to sites of S. aureus infection. The accumulation of FAM-CARG at sites of infection showed that CARG is capable of delivering a lowmolecular-weight compound to infected tissue. This conclusion is based on the fact that FAM is in the same size range as a typical lowmolecular-weight drug. We next examined the ability of CARG to deliver a nanoparticle (NP) payload by testing 20 nm CARG-coated silver NPs (CARG-AgNPs) on RAW 264.7 mouse macrophages. The RAW 264.7 cells are representative of activated macrophages, and this cell line has been used in earlier S. aureus infection studies 42 . When incubated in media containing CARG-AgNPs and S. aureus, both the bacteria and the CARG-AgNPs, presumably as a complex, are taken up more effectively than control AgNPs, at least NATuRe BiomediCAL eNGiNeeRiNG findings demonstrate that the CARG peptide can target a nanoparticle to S. aureus-induced infections.
To investigate the translational potential of CARG for targeted drug delivery, we examined CARG-mediated delivery of the antibiotic vancomycin in the S. aureus lung infection model. The antibiotic was incorporated into porous silicon nanoparticles (pSiNPs) (mean diameter: ~180 nm) using a self-sealing chemical process involving calcium silicate formation that physically traps the drug payload without chemically altering its structure ( Supplementary Fig. 8 ) 43 . In the present case, the process loaded 12% by mass of vancomycin. The pSiNPs dissolved and the drug payload was released gradually over a 12 h period under simulated in vivo conditions, and the antibiotic retained 100% of its activity upon release ( Supplementary Fig. 9 ). Although the drug release kinetics may be different in vivo, the results suggest delayed release of active antibiotic from the pSiNPs. Next, we modified the vancomycin-loaded pSiNPs with the CARG peptide for active targeting into infected tissue ( Fig. 5a-d ).
Time-gated luminescence imaging of the long-lived photoluminescence signal from the pSiNPs 23 ( Fig. 5e ,f) showed that intravenously injected CARG-conjugated pSiNPs (CARG-pSiNPs) accumulated in infected lungs at markedly higher levels than control pSiNPs (Fig. 5f ), and the CARG-pSiNPs spread into the extravascular sites in infected, but not normal, lungs ( Fig. 5g and Supplementary Fig. 10 ). Low but detectable signal intensities from control pSiNPs were observed in infected lungs and some CARGpSiNPs were found in normal lungs ( Supplementary Fig. 10 ). This background may be caused by NP uptake into the mononuclear phagocyte system (MPS) in the lungs 44, 45 . We further characterized the percent injected dose per gram (%ID g −1 ) of elemental silicon in different organs 6 hs after pSiNP administration in S. aureus-infected mice by inductively coupled plasma-optical emission spectroscopy (ICP-OES). Biodistribution in healthy mice was also analysed for comparison. As shown in Supplementary Fig. 11a , there was significantly higher accumulation of CARG-pSiNPs in the ) is attributable to CARG targeting. Overall, these results establish the specific targeting of staphylococcal infection by CARG-pSiNPs.
In our infection model, intratracheally introduced S. aureus caused serious pneumonia, resulting in 67% mortality (n = 9 mice) 24-48 h post-infection, and only 11% survival by day 6. Treatment of infected mice with intravenous injections of the CARG-targeted vancomycin-pSiNPs 1 day post-infection resulted in 100% recovery and long-term survival, whereas only 33% survival was seen when an equivalent dose (3 mg kg ), the survival rates were 70-80% (n = 5-7, Supplementary Fig. 12a and 12b ) and 100% (n = 3-5; Supplementary Figs. 12a and S13), respectively. Therefore, higher doses of vancomycin were progressively more effective. In a separate study, shown in Supplementary Fig. 12b , CARG-pSiNPvancomycin (1 mg kg
; n = 5) was 100% effective, whereas 9 mg kg −1 of free vancomycin was again only partially effective (Figs. S12a and 12b). Thus, vancomycin delivered in CARG-pSiNPs is about 10-fold more effective than free vancomycin, and complete survival in our S. aureus infection model required at least a ~10-fold higher dose of free vancomycin than was delivered in the CARG-pSiNPs. We also evaluated the in vivo toxicity of the pSiNPs. Healthy mice injected with vancomycin-loaded pSiNPs or the free antibiotic at a therapeutically effective dose (3 mg kg ) showed normal aspartate aminotransferase and alanine transaminase levels (Supplementary Table 1 ), indicating lack of toxicity to the liver, the organ that nonspecifically takes up nanoparticles. Tissue histology supported the conclusion that the infection had completely resolved in the lungs of surviving treated mice (Fig. 6b) , with no infectious foci or toxic damage observed in any of the major organs.
Discussion
The peptide CARG, which recognizes S. aureus bacteria, enhances the accumulation of systemically administered payloads (with chemistries ranging from a drug-sized molecule to nanoparticles) at sites of staphylococcal infection. We also show that porous silicon nanoparticles loaded with vancomycin and targeted with the CARG peptide are several times more effective than free vancomycin in eradicating a staphylococcal lung infection. This approach may have therapeutic advantages in situations that require the use of last-resort antibiotics to deal with difficult-to-treat infections, such as the ones caused by MRSA.
We used in vivo phage display in our screens for peptides that recognize staphylococcal infections to increase the likelihood that the resulting peptides are relevant to real-life infections. Screening phage libraries on cultured bacterial cells readily yields peptides that bind to bacteria 33 . However, the environment strongly influences bacterial gene expression, and it is entirely possible that a prominent surface component of cultured bacteria is not expressed, or is only a minor component in vivo. By combining screening for peptide homing to infected tissue in vivo with selection on cultured bacteria, we sought to ascertain that our peptides would be specific for the bacteria as they exist in the infected tissue, and that the peptide could reach the bacteria in the tissue. The CARG peptide we obtained fulfills these criteria.
The screening results and the CARG variations tested so far allow some conclusions regarding the structure function relationships. As shown in Fig. 1 , there is some conservation of the residues close to the ARG motif, and the ARG motif is positioned close to the centre or toward the N terminus of the peptide. The lack of bacterial binding by the control peptide suggests that the ARG motif cannot be adjacent to the C-terminal cysteine. The loss of activity following linearization of the peptide shows that the cyclic structure is important for the activity, which is likely to be because the ARG motif is presented in an active conformation.
Several experiments demonstrated that the CARG peptide is highly specific for staphylococcal infections. First, the peptide bound to cultured S. aureus (two different strains, one a MRSA strain) and not to P. aeruginosa bacteria. Second, intravenously injected CARG accumulated in staphylococcal lung and skin infections, and not in normal tissues. Third, the peptide largely colocalized with the bacteria in the infected tissue. Fourth, CARG did not recognize lung tissue infected with P. aeruginosa. Thus, CARG appears suitable for specific targeting of S. aureus in infected tissues. Of note, CARG peptide accumulates at sites in infected tissue even where there are no bacteria detectable by antibody stain. A likely explanation for this distribution pattern is that CARG is targeting a bacterial component that is either derived from disintegrated bacteria, or that is shed from the surface of intact bacteria. This bacterial component then binds to host tissue and is targeted by CARG. The target is clearly a bacterial surface component because CARG strongly labels the bacterial surface in vitro. That the peptide targeting is not limited to 
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intact bacteria is an advantage because it allows more peptide and payload to be targeted into the infected tissue than would be the case if the peptide only recognized intact bacteria.
The CARG peptide accumulated in host cells containing intracellular bacteria, colocalizing with the bacteria. This is a potentially important property of CARG, because the intracellular location protects bacteria against the host immune system and against antibiotics, which enables long-term colonization of the host, causing persistent and recurrent infections 38, 39 . S. aureus is generally considered an extracellular pathogen. However, there is substantial evidence to the effect that these bacteria can survive intracellularly 34, 46, 47 . The fact that CARG can reach intracellular bacteria suggests that CARG-mediated delivery of antibiotics has the potential to facilitate the eradication of bacteria from intracellular locations.
Antibiotics loaded into nanoparticles have found clinical use 48 . The nanoparticle vehicle in these products is typically a liposome. The inorganic, non-liposomal pSiNPs used for antibiotic delivery in the present work have several attractive features: they are biocompatible and degrade in the body into silicic acid, which is naturally found in human tissues and efficiently excreted from the body through the urine 22 . They have a high loading capacity for therapeutic payloads that are released upon dissolution of the nanostructure, and this release can be controlled 22, [49] [50] [51] . Finally, pSiNPs, and nanoparticles in general, are well suited for targeting with peptides because the avidity effect provided by the multivalent presentation on the NP surface compensates for the relatively low affinity of peptides for their target 27 . Our results illustrate the advantages of targeted pSiNPs as a delivery vehicle for antibiotics. Promising gains in efficacy have been obtained by targeting antibiotics to bacteria 10, 11 . Our delivery system combines the pSiNPs and targeting approaches. The CARG-coated pSiNPs gave an increase in vancomycin efficacy that was at least 10-fold. The 'last-resort' antibiotics have typically been assigned to that status because, while effective, they are also toxic. In addition, some antibiotics are often poorly soluble and therefore difficult to administer 52 . Delivery in pSiNPs has mitigated both of these problems 17, 18, 21, 24, 43 , and targeted pSiNPs add further gains by lowering the total dose needed-thus reducing toxic side effects while increasing efficacy of the treatment.
We analysed the biodistribution of pSiNPs by time-gated luminescence imaging and ICP-OES. The time-gated method images the intrinsic, long-lived photoluminescence from the pSiNP carrier and eliminates tissue autofluorescence 23 , and allows the payload to be reliably quantified in intact organs. The quantitation of %ID g −1 of elemental silicon in different organs measured by ICP-OES showed a significantly higher accumulation of CARG-pSiNPs in the infected lungs than of control pSiNPs (> 4-fold). Accumulation of CARG-pSiNPs in the lungs of healthy animals did not differ from control pSiNPs. Thus, the substantial amount of the CARG-pSiNPs in the infected lungs is attributable to CARG targeting. Our biodistribution data are in good agreement with a previous analysis of silicon nanoparticle biodistribution 22 . The elemental analysis and photoluminescence data are also in good agreement, although elemental analysis showed higher silicon content in the spleen. This is possibly due to rapid biodegradation of the pSiNPs in the spleen, or photoluminescence quenching by the spleen microenvironment. The data indicate that targeted delivery increases the amount of silicon delivered to infected lungs, translating to more efficacious delivery of nanoparticle-loaded vancomycin, in agreement with the enhanced antibacterial activity we observed. In contrast, targeted and control pSiNPs gave similar silicon levels in normal organs (Fig. S11a) . Thus, the silicon biodistribution data indicate that for a given vancomycin dose in pSiNPs, the targeted pSiNPs provided improved efficacy with a comparable systemic drug burden.
The tendency of nanoparticles to clear through the liver raises the possibility of liver toxicity, which would not necessarily be seen with the free drug. Vancomycin is generally not toxic to the liver [53] [54] [55] , and we saw no evidence of acute liver toxicity in this study. Even if the antibiotic payload is toxic to the liver, the reduced dose made possible by the addition of the targeting peptide component may compensate for the selective liver accumulation of the carrier NPs. It should be noted that clearance through the liver and spleen results in substantial NP accumulation in these organs. Although no acute toxicity was noted in this study, extended administration of antibiotic-loaded NPs to treat chronic infections will require long-term safety studies.
In summary, we have developed a targeted drug delivery system that is based on: (1) the selection of a peptide that is capable of recognizing and reaching an infectious agent in infected tissues; (2) a biocompatible nanoparticle vehicle with a high loading capacity for an antibiotic; and (3) the use of the peptide to concentrate the nanoparticles at the site of infection. Substantial efficacy gains in antibiotic treatment of a staphylococcal pneumonia mouse model validate the technology, which may be broadly applicable to other infectious diseases.
Methods
Bacterial strains. Staphylococcus aureus subspecies aureus (ATCC 25923), methicillin-resistant Staphylococcus aureus (MRSA USA300-0114; ATCC BAA-1756), and Pseudomonas aeruginosa (ATCC 10145) strains procured from the American Type Culture Collection (ATCC) were used. For inoculation experiments, subcultures were grown from freezer stocks in Brain Heart Infusion (BHI) agar plates and incubated at 37 °C overnight. All subsequent liquid subcultures were derived from colonies isolated from these plates.
Animal models of infection. All animal experiments were conducted under an approved protocol of the Institutional Animal Care and Use Committee of Sanford Burnham Prebys Medical Discovery Institute. To create a lung infection model, we inoculated S. aureus bacteria intratracheally 31 . The bacteria were grown overnight in BHI media with constant aeration. The cultures were diluted in BHI media by a factor of 100, and grown at 37 °C until the mid-log phase. The staphylococci were centrifuged and the pelleted bacteria were washed three times with cold, sterile phosphate-buffered saline (PBS) and finally suspended in 0.5 ml PBS. An aliquot of the culture was plated in BHI agar plates, and resulting colonies were counted (colony-forming units; CFU).
Male BALB/c mice (8-10 weeks old; Envigo) were anaesthetized with 4% isoflurane (Aerrane; Baxter, UK) and secured on a surgery board angled at 60°. The fur on the neck was shaved, and the skin was disinfected with betadine and alcohol wipes. A 1 cm longitudinal incision was made over the trachea, the overlying muscle was retracted, and the trachea exposed. A tuberculin syringe fitted with a short-bevel 26-gauge needle was used to introduce 30 µ l of bacterial suspension (10 7 CFU) into the trachea. Application of pressure to the abdomen of the mouse to deflate the lungs and its removal concurrent with the introduction of inoculum into the trachea assured inspiration of the inoculum into the lungs. The incision was closed with sutures and the mice were placed on a warming pad to recover from anaesthesia before being placed back into their cage. A similar method was used in the P. aeruginosa pneumonia model. A skin infection model was obtained by inoculating 8-10-week-old male BALB/c mice under isoflurane anaesthesia with a subcutaneous injection in shaved right flank of 10 7 CFU S. aureus in 50 µ l of PBS. This method produces consistent dermonecrotic abscesses within 2 days 56 . The weights of all infected mice were recorded before inoculation and at 24 h intervals post-infection during the course of disease.
In vivo phage display. In vivo phage screening of peptide libraries was carried out as described using mice with S. aureus-induced lung infection 57 . The T7 library with the general structure of CX 7 C (C = cysteine, X = any amino acid) was injected 48 h post-infection and allowed to circulate for 30 min, after which the mice were perfused with 15-20 ml of warm PBS through the heart and tissues were collected for phage recovery. After three in vivo rounds of screening, the phage pool recovered was subjected to one round of in vitro biopanning on cultured S. aureus bacteria culture, followed by another round of in vivo screening. The phage pools obtained after the in vitro and the fourth in vivo rounds were subjected to high-throughput sequencing using Ion Torrent (Thermo Fisher Scientific).
Peptide synthesis. Peptides were amidated on the C terminus and synthesized on a microwave-assisted automated peptide synthesizer (Liberty; CEM, Matthews, NC) following Fmoc/tertiary butyl strategy on rink amide MBHA resin with HBTU (N,N,N′ ,N′ -tetramethyl-O-(1H-benzotriazol-1-yl) uronium hexafluorophosphate) activator (or alternatively O-(benzotriazol-1-yl)-N,N,N′ ,N′ -tetramethyluronium hexafluorophosphate), collidine activator base and 5% piperazine for deprotection. When included, fluorescein was incorporated during the synthesis at the N terminus NATuRe BiomediCAL eNGiNeeRiNG of the sequence as 5(6)-carboxyfluorescein with a spacer, 6-aminohexanoic acid, separating the fluorophore and the sequence. Cleavage using a 95% trifluoroacetic acid (TFA) followed by purification on C18 reverse phase column using acetonitrile water mixtures containing 0.1% TFA gave peptides with 90-95% purity. The peptides were analysed by matrix assisted laser desorption mass spectrometry (MALDI).
Peptide targeting to infection sites and immunofluorescence. Animals with pneumonia were intravenously injected with 100 nmol of FAM-labelled synthetic peptide, at 24-48 h post-infection, and the peptide was allowed to circulate for 30-60 min. Following terminal cardiac perfusion with PBS, lungs and other organs were isolated, fixed in 4% (w/v) paraformaldehyde (PFA) in PBS overnight, washed with PBS, cryo-protected in sucrose solution (30% (w/v) in PBS) overnight, and processed through OCT embedding. 10 µ m sections were cut and analysed by fluorescence microscopy. The primary antibodies for immunofluorescence were rabbit anti-Staphylococcus aureus, (ab20920, Abcam); rabbit anti-fluorescein (A889, Invitrogen); rabbit anti-Pseudomonas (ab68538, Abcam); rat anti-mouse CD11b (550282, BD Pharmingen); rat anti-mouse CD45 (550539, BD Pharmingen); and rat anti-mouse Ly-6G (551459, BD Pharmingen). These antibodies were incubated in diluted (1%) blocking buffer overnight at dilutions 1:100 or 1:200 at 4 °C, the sections were washed with PBS-T and incubated with secondary antibodies diluted 1:500 or 1:1,000, in 1% blocking buffer for 1 h at room temperature. Sections were then washed with PBS-T, counterstained with DAPI (1 µ g ml ) in PBS for 10 min, washed with PBS, mounted using mounting media (Molecular Probes, Life Technologies) and examined using a confocal microscope (Zeiss LSM-710).
Preparation of porous silicon nanoparticles. Porous silicon nanoparticles (pSiNPs) were prepared by electrochemical etch of crystalline, (100)-oriented silicon wafers (p-type, boron-doped, ~ 1 mΩ cm resistivity) as described previously 58, 59 . In brief, the silicon wafer was anodized in an electrolyte composed of 3:1 (v:v) of 48% aqueous HF:ethanol. The etching waveform consisted of a square wave in which a lower current density of 50 mA cm −2 was applied for 1.8 s, followed by a higher current density pulse of 400 mA cm −2 for 0.36 s. The pulsed waveform was repeated for 140 cycles, and the resulting porous silicon nanostructure was lifted-off from the silicon substrate by application of a current density of 3.7 mA cm −2 for 250 s in an electrolyte consisting of 1:30 (v:v) of 48% aqueous HF:ethanol. The freestanding porous silicon films were then fractured into nanoparticles of mean diameter 170 nm by ultrasonication in deionized water overnight.
Preparation of vancomycin-loaded porous silicon nanoparticles.
Vancomycin was loaded and trapped in the pSiNPs following a published procedure previously used to load siRNA 43 . An aqueous dispersion of pSiNPs (1 mg ml −1 in deionized water) was added to an aqueous solution of vancomycin (0.5 mg ml −1 ) in a 1:1 (v:v) ratio, and ultrasonicated for 10 min. An equal volume of aqueous calcium chloride solution (2 M) was then added to the mixture, which was agitated (< 5 min) and ultrasonicated in an ice bath for 2 h. Drug-loaded nanoparticles were purified by centrifugation and washing steps with deionized water, 70% ethanol and 100% ethanol, sequentially. To analyse the vancomycin loading capacity, the supernatants from centrifugation were collected and assayed for free vancomycin by measuring absorbance at 280 nm. The mass loading was verified by spectrophotometric quantification (λ max = 280 nm) of vancomycin released from the nanoparticles.
Coupling of peptide to the vancomycin-loaded porous silicon nanoparticles. Aliquots (1 ml) of pSiNPs (1 mg ml −1 in ethanol) were treated with 20 μ l of 3-(ethoxydimethyl)-propylamine silane by vortexing overnight at room temperature. The amine-terminated nanoparticles were rinsed with ethanol and water, and then further functionalized by either MAL-PEG-SCM (maleimidepolyethylene glycol-succinimidyl carboxy methyl ester, MW 5000) or mPEG-SCM (methoxy PEG-succinimidyl carboxy methyl ester, MW 5000) 23 . The maleimideactivated nanoparticles were then mixed with the CARG peptide solution (0.5 mg ml −1 in water, 1 ml) and vortexed for 2 h to conjugate the peptide via the free cysteine residue at the terminal group of the peptide ( Supplementary Fig. 14) 60 . Peptide coupling was quantified and confirmed by measuring the fluorescence of the FAM label of the peptide.
Characterization of the porous silicon nanoparticles. Hydrodynamic size of the nanoparticles was measured by dynamic light scattering (DLS, Zetasizer ZS90, Malvern Instruments). Transmission electron microscopy (TEM) images were obtained with a JEOL-1200 EX II. Photoluminescence spectra (λ ex = 365 nm) were monitored using a spectrometer (QE Pro, Ocean Optics) with a 460 nm long-pass filter. Quantification of vancomycin was conducted by measuring absorbance at 280 nm with a spectrophotometer (NanoDrop 2000, Thermo Scientific) based on the standard curve of vancomycin.
In vitro antibacterial activity test. S. aureus bacteria were cultured overnight to achieve stable growth kinetics, and diluted bacteria were then separated to individual tubes. Bacterial growth and minimum inhibitory concentration of vancomycin were determined using optical density measurements.
In vivo antibiotic activity test. Six-to eight-week-old male BALB/c mice were used to evaluate in vivo anti-infective activity and to assess possible toxicity of the targeted nanoparticles. The S. aureus pneumonia model was generated by intratracheal inoculation as described above. S. aureus bacteria were introduced at a lethal dose of 5 × 10 7 CFU, which had been determined from a previous dose escalation study assessing the survival rate of mice 48 h after challenge. At this lethal dose, 67% (n = 9) of mice died 24-48 h post-infection, and 89% of infected animals died within 6 days. After 24 h of infection, the mice received an intravenous injection of either PBS, free vancomycin, CARG-pSiNP-vancomycin and PEG-pSiNP-vancomycin (control-pSiNP-vancomycin). The mice were observed over 20 days to evaluate survival. To compare antibacterial efficacy of each system, a separate dosing study involving free vancomycin (in the range 0.1-15 mg kg ) and vehicle control (PBS) were injected intravenously into S. aureus-infected mice (24 h post-infection) and healthy mice. Nanoparticles were allowed to circulate for 6 h, and then the mice were sacrificed by cardiac perfusion with PBS under anaesthesia. Major organs such as brain, heart, lung, liver, kidney and spleen were collected, weighed, homogenized in a solution of PBS (0.3 ml), aqueous HNO 3 (0.25 ml, ~15.7 M) and H 2 O 2 (0.05 ml, 30 %), and digested for 2 days. The digested slurry was centrifuged (20,200g, 10 min) and the supernatant was filtered using a syringe filter (Millex-HV Syringe Filter Unit, 0.45 μ m), and then diluted with 2% (v/v) HNO 3 solution in water to prepare a final volume of 2 ml. Each solution was analysed by inductively coupled plasmaoptical emission spectroscopy (ICP-OES, Perkin Elmer Optima 3000DV). Silicon standard solutions (1, 0.5, 0.1 and 0.01 μ g ml ) were used to calibrate Si content by dilution of a stock Si solution (1,000 μ g ml
) with 2% aqueous HNO 3 .
Statistical analysis. All data represent mean value ± standard deviation. The significance analyses were performed using Statistica 8.0 or GraphPad Prism software, employing a one-way ANOVA or two-tailed heteroscedastic Student's ttest as detailed in the figure legends. 
Data exclusions
Describe any data exclusions.
The lung-infection model in mice was generated by intratracheal inoculation of S. aureus. Typically, we found 2 or 3 animals routinely succumbed within the first 24 h after inoculation. These animals were excluded from the antibacterial-efficacy survival curves and from subsequent statistical analyses. No other data were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All peptide and pSiNPs homing experiments to S. aureus infection were reproducible. The data from the antibacterial-therapy experiments showed variability due to inter-experiment variation in the severity of the infection.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For the therapy studies, each experimental group was allocated with 5-9 animals per group. Animals were allocated to each group by random selection based on body weight, ruffled fur, lethargy and slight hunched posture.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Groups of mice were blinded for collection and analysis of data when used for the in vivo study of therapeutic efficacy. Each experimental group was indexed as group 1-4 by an independent person, and the groups were given to random observers for counting.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
GraphPad Prism 7 for Windows was used for the statistical analysis of survival curves.
GraphPad Prisim 7 and Microsoft Excel 2016 were used for the statistical analysis of biodistribution data. Andor Solis software was used for time-gated imaging and PL-intensity analysis.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There is no restriction on the availability of materials.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The primary antibodies for immunofluorescence were: rabbit anti-Staphylococcus aureus (ab20920, Abcam); rabbit anti-Fluorescein (A889, Invitrogen); rabbit antiPseudomonas (ab68538, Abcam); rat anti-mouse CD11b (550282, BD Pharmingen); rat anti-mouse CD45 (550539, BD Pharmingen); and rat anti-mouse Ly-6G (551459, BD Pharmingen). 
